4.7 Article

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion

Journal

NEUROLOGY
Volume 78, Issue 10, Pages 690-695

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318249f683

Keywords

-

Funding

  1. National Institute of Neurological Disorders and Stroke (NINDS) [NS016367]
  2. CHDI Foundation, Inc.
  3. Huntington's Disease Society of America
  4. National Research Foundation of Korea [NRF-2009-352E0010]
  5. Fundacao para e a Tecnologia of Portugal (FCT) [SFRH/BD/44335/2008]
  6. National Institutes of Health NINDS [NS016367, NS024279, NS032765, NS033648, NS040068, NS044466, NS036630, NS052592, NS060118, NS16375, NS055252., NS069422, NS016375, NS044431, NS068897, NS050095]
  7. High Q Foundation
  8. National Parkinson Foundation
  9. Santhera Pharmaceuticals
  10. Medivation/Pfizer
  11. Neuro-Search
  12. Schwarz Biosciences
  13. IMPAX Pharmaceuticals
  14. Neuraltus Pharmaceuticals
  15. Teva Pharmaceuticals
  16. National Institutes of Health NCCAM [AT000613]
  17. NHGRI [HG02449]
  18. Michael J. Fox Foundation/Northwestern Dixon Foundation
  19. Forest Laboratory
  20. Ministero della Salute, Italy
  21. Fondazione Cariplo, Milan, Italy
  22. CIBERER, ISCIII, Madrid, Spain
  23. Abbott Laboratories
  24. Australian Research Council LIED [LE0989147, LE100100130]
  25. Italian Drug Agency (AIFA) [FARM659PTX]
  26. Lundbeck Pharmaceuticals
  27. Bayer
  28. EMD Serono
  29. Michael J. Fox Foundation
  30. National Institutes of Health NICHD [HD062550, HD06528]
  31. South Carolina Council [18120 FL00]
  32. Fullerton Foundation
  33. Amarin Corporation
  34. NeuroSearch Sweden AB
  35. Medivation
  36. NCRR [RR024156, PO412196-G]
  37. Parkinson Study Group
  38. European Commission
  39. European Union
  40. High Q Foundation/CHDI Foundation
  41. Jerry MacDonald Huntington Research Fund
  42. NIGMS [GM061354]
  43. Simons Foundation
  44. MRC [G1001257, G0800784] Funding Source: UKRI
  45. Medical Research Council [G0800784B, G1001257, G0800784] Funding Source: researchfish
  46. National Institute for Health Research [CL-2009-18-005] Funding Source: researchfish
  47. Fundação para a Ciência e a Tecnologia [SFRH/BD/44335/2008] Funding Source: FCT
  48. Australian Research Council [LE0989147, LE100100130] Funding Source: Australian Research Council

Ask authors/readers for more resources

Objective: Age at onset of diagnostic motor manifestations in Huntington disease (HD) is strongly correlated with an expanded CAG trinucleotide repeat. The length of the normal CAG repeat allele has been reported also to influence age at onset, in interaction with the expanded allele. Due to profound implications for disease mechanism and modification, we tested whether the normal allele, interaction between the expanded and normal alleles, or presence of a second expanded allele affects age at onset of HD motor signs. Methods: We modeled natural log-transformed age at onset as a function of CAG repeat lengths of expanded and normal alleles and their interaction by linear regression. Results: An apparently significant effect of interaction on age at motor onset among 4,068 subjects was dependent on a single outlier data point. A rigorous statistical analysis with a well-behaved dataset that conformed to the fundamental assumptions of linear regression (e. g., constant variance and normally distributed error) revealed significance only for the expanded CAG repeat, with no effect of the normal CAG repeat. Ten subjects with 2 expanded alleles showed an age at motor onset consistent with the length of the larger expanded allele. Conclusions: Normal allele CAG length, interaction between expanded and normal alleles, and presence of a second expanded allele do not influence age at onset of motor manifestations, indicating that the rate of HD pathogenesis leading to motor diagnosis is determined by a completely dominant action of the longest expanded allele and as yet unidentified genetic or environmental factors. Neurology (R) 2012; 78: 690-695

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available